Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kah Whye Peng
Mayo Clinic Arizona, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vyriad, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see attached.
Mayo Clinic Multiple Myeloma SPORE
OVERALL PROJECT NARRATIVE Most patients with multiple myeloma continue to die of the disease. This SPORE will develop new treatment approaches using oncolytic virotherapy and novel drugs that activate the immune system. In addition the SPORE will determine the clinical significance of mutations of the MYC locus, and recurrent point mutations in patients with multiple myeloma.
Filed on January 16, 2017.
Tell us what you know about Kah Whye Peng's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Kah Whye Peng”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Imanis Life Sciences | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Vyriad (fka Omnis Pharma and Magnis) | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Vyriad, Inc. (fka Omnis Pharma and Magnis Thera) | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Imanis Life Sciences LLC | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Omnis Pharma | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Vyriad, Inc. | $0 - $4,999 |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Vyriad, Inc. | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Vyriad, Inc. | Value cannot be readily determined |
| Kah Whye Peng | Mayo Clinic Rochester | Conflict of Interest | Vyriad, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.